Supporting this notion, CL treatment has been shown to improve cognitive outcomes in 3xTg AD mice (Tournissac et al., 2021), and mirabegron (an FDA approved β3‐AR agonist) also improves pancreatic β‐cell function, reduces lipotoxicity, and increases the number of type 1 fibers in the skeletal muscle of obese insulin‐resistant middle‐aged humans (Finlin et al., 2020). The gene discussed is ADRB3; the disease is Alzheimer disease.